Orthopaedic Research Laboratory, Aarhus University Hospital, Norrebrogade 44, Building 1A, Aarhus C, 8000, Denmark. E-mail address for M. Sørensen:
J Bone Joint Surg Am. 2013 Oct 16;95(20):1862-8. doi: 10.2106/JBJS.L.00641.
Revision arthroplasty surgery is often complicated by loss of bone stock that can be managed by the use of bone allograft. The allograft provides immediate stability for the revision implant but may be resorbed, impairing subsequent implant stability. Bisphosphonates can delay allograft resorption. We hypothesized that zoledronate-impregnated allograft impacted around revision implants would improve implant fixation as characterized by mechanical push-out testing and histomorphometry.
Twenty-four axially pistoning micromotion devices were inserted bilaterally into the knees of twelve dogs according to our revision protocol. This produced a standardized revision cavity with a loose implant, fibrous tissue, and a sclerotic bone rim. Revision surgery was performed eight weeks later; after stable titanium revision components were implanted, saline solution-soaked allograft was impacted around the component on the control side and allograft soaked in 0.005 mg/mL zoledronate was impacted on the intervention side. The results were evaluated after four weeks.
The zoledronate treatment resulted in a 30% increase in ultimate shear strength (p = 0.023), a 54% increase in apparent shear stiffness (p = 0.002), and a 12% increase in total energy absorption (p = 0.444). The quantity of allograft in the gap was three times greater in the zoledronate group compared with the control group (p < 0.001). The volume fraction of new bone in the zoledronate group (25%; 95% confidence interval [CI], 22% to 28%) was similar to that in the control group (23%; 95% CI, 19% to 26%) (p = 0.311).
The data obtained in this canine model suggest that pretreating allograft with zoledronate may be beneficial for early stability of grafted revision arthroplasty implants, without any adverse effect on bone formation. Clinical studies are warranted.
The zoledronate treatment is simple to apply in the clinical setting. The treatment could increase early stability of revision joint replacements without impairing new bone formation. In the long term, this can potentially improve the longevity of revision joint replacements and reduce the number of subsequent revisions.
翻修关节置换手术常因骨质丢失而变得复杂,可通过使用同种异体骨移植来处理。同种异体骨为翻修植入物提供了即时稳定性,但可能被吸收,从而影响后续植入物的稳定性。双膦酸盐可以延迟同种异体骨吸收。我们假设,包埋唑来膦酸的同种异体骨移植可以改善翻修植入物周围的植入物固定,这可以通过机械推出测试和组织形态计量学来评估。
根据我们的翻修方案,将 24 个轴向活塞微动装置双侧插入 12 只狗的膝关节。这会产生一个具有松动植入物、纤维组织和硬化骨缘的标准化翻修腔。八周后进行翻修手术;在植入稳定的钛制翻修组件后,将生理盐水浸泡的同种异体骨移植到对照组侧的组件周围,将浸泡在 0.005mg/ml 唑来膦酸的同种异体骨移植到干预组侧的组件周围。四周后评估结果。
唑来膦酸治疗组的最终抗剪强度增加了 30%(p=0.023),表观抗剪刚度增加了 54%(p=0.002),总能量吸收增加了 12%(p=0.444)。唑来膦酸组的同种异体骨在间隙中的数量是对照组的三倍(p < 0.001)。唑来膦酸组的新骨体积分数为 25%(95%置信区间[CI],22%至 28%),与对照组相似(23%[95%CI,19%至 26%])(p=0.311)。
在这种犬模型中获得的数据表明,用唑来膦酸预处理同种异体骨可能有益于移植翻修关节置换植入物的早期稳定性,而不会对骨形成产生任何不良影响。需要进行临床研究。
唑来膦酸治疗在临床环境中应用简单。该治疗方法可以增加翻修关节置换的早期稳定性,而不会影响新骨形成。从长远来看,这可以潜在地提高翻修关节置换的寿命,并减少后续翻修的次数。